Sympathetic Mapping/ Ablation of Renal Nerves Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I® and SYMPIONEER S1® Stimulator/ Generator in patients with essential hypertension for at least 6 months of the disease history and pharmacotherapy, however, their blood pressure still cannot be controlled, then after standardized antihypertensive drug therapy (at least two drugs) for at least 28 days, office systolic blood pressure is still ≥ 150mmHg, ≤180mmHg.
Epistemonikos ID: 19242c0dc371949c55c9b6ab0ec3767fa0a6e0d8
First added on: May 13, 2024